Study of a new drug for recurrent glioblastoma
Treatments studied
Part of Cancer clinical trials.
This trial tests a new drug called BL-B01D1 for people whose glioblastoma has come back after standard treatment. The goal is to see if the drug can help control the tumor.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been diagnosed with glioblastoma that has returned after standard treatment.
- You are at least 18 years old.
- Your performance status is 60 or higher on the Karnofsky scale (able to care for most daily needs).
- Your major organs (heart, kidneys, liver, blood cells) are functioning well enough.
- You have not had certain other cancer treatments within the past few weeks.
- You are not pregnant or breastfeeding, and you agree to use effective birth control during the study and for 6 months after.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This early study looks at a treatment plan (including resection/surgery and an added medicine) for glioblastoma that has come back after standard therapy. The goal is to see how well it controls tumor growth and whether it is tolerable.
This trial tests whether the immunotherapy drug atezolizumab can help people with glioblastoma that has come back after initial treatment. You will need to have a biopsy before starting the drug to confirm the tumor has returned.
This trial tests an experimental oral drug called CT-179, which targets a protein involved in brain tumor growth. It may help people with glioblastoma, a type of brain cancer, when standard treatments have not worked or as part of initial treatment.
This early-stage trial tests a new drug called YSCH-01, alone or combined with an immunotherapy drug (atezolizumab), for glioblastoma that has come back after previous treatment. The study places a small tube in the brain to deliver the drug directly and monitors safety and how well it works.
This trial tests a new injection called BC008-1A for people with a grade 4 glioma (a type of brain cancer) that has come back after standard treatment. The goal is to see if the drug can help control the tumor and improve outcomes.
This trial tests a new drug called BioTTT001 for people whose high-grade brain tumor has come back after standard treatment. The drug is given through a small device placed in the head to deliver it directly to the tumor area.
Hear when a new Recurrent Glioblastoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.